By Larry Husten, Contributor Once again a trial testing the erythropoiesis-stimulating agent darbepoetin alfa (Aranesp, Amgen) has produced a negative result. Results of the RED-HF (Reduction of Events by Darbepoetin Alfa in Heart Failure) trial were presented at the ACC in San Francisco and published simultaneously in the New England Journal of Medicine. …read more
Source: FULL ARTICLE at Forbes Latest
Tag Archives: ACC
Eplerenone May Help Prevent Heart Failure In Acute Heart Attack Patients
By Larry Husten A new trial presented at the ACC in San Francisco suggests that the mineralocorticoid receptor agonist eplerenone Pfizer, Inspra) may help prevent the development of heart failure when given acutely in STEMI patients without preexisting heart failure. …read more
Source: FULL ARTICLE at Forbes Health
New Antiplatelet Drug May Improve Stent Outcomes
By Larry Husten In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet inhibitor cangrelor was tested for its effect on ischemic events associated with PCI. Cangrelor is a potent, fast-acting and reversible agent. Results of the trial were presented at the ACC in San Francisco and published simultaneously in the New England Journal of Medicine. …read more
Source: FULL ARTICLE at Forbes Technology
HPS2-THRIVE: A 'Disappointing But Clear' Result
By Larry Husten The results of HPS2-THRIVE were “disappointing but clear,” said Jane Armitage, who presented the results this morning at the ACC in San Francisco. …read more
Source: FULL ARTICLE at Forbes Health
Following An Embargo Break PREVAIL Trial Won't Be Presented At ACC
The already complicated story behind the PREVAIL trial, which was designed to confirm the safety and efficacy of the Watchman left atrial appendage closure device, just got even more complicated. This morning, after the trial’s sponsor, Boston Scientific, prematurely distributed to investors a press release summarizing the results of the trial, the ACC announced that the scheduled presentation of the results at the main opening session of the meeting would not take place. …read more
Source: FULL ARTICLE at Forbes Latest
Hospitals Seeing Rapidly Growing Numbers Of Adults With Congenital Heart Disease
By Larry Husten Hospitals are treating increasing numbers of adults with congenital heart disease, thanks to tremendous progress in treatment for this condition in recent decades. A clear picture of this dramatic change emerges in a new study, presented at the ACC in San Francisco and published simultaneously in JAMA. …read more
Source: FULL ARTICLE at Forbes Health
American College of Cardiology Prevails Upon Boston Scientific To Present More Data At Late Breaker
By Larry Husten
In an unusual reversal of a statement it made two days ago, Boston Scientific announced this afternoon that it would present all three co-primary endpoints of the PREVAIL clinical trial this Saturday at the American College of Cardiology scientific sessions in San Francisco. The PREVAIL trial, which was designed to confirm the safety and efficacy of the Watchman left atrial appendage closure device, is one of the most highly-anticipated late-breaking clinical trials at the ACC this year. …read more
Source: FULL ARTICLE at Forbes Health
Sources: Notre Dame could join ACC this year
By Brett McMurphy The ACC will allow Notre Dame to join the league this summer if the Fighting Irish can exit the Big East Conference, sources told ESPN. …read more
Source: FULL ARTICLE at ESPN Headlines
Conference Realignments Reflect Underlying Compatability (Mostly)
The poaching of past Big East schools by the ACC and Big East and similar events in other conferences has engendered accusations of greed, disloyalty, and nastier things. Jilted institutions and league officials have sounded a lot like spurned lovers. While soap operas have appeared as little more of than a mad scramble for cash, a degree of order has emerged. In fact, the latest headlines pointing toward Xavier and Butler joining the “Catholic 7” Big East basketball schools demonstrate a sorting out apples with apples and oranges with oranges – call it the “eHarmony” model of relationship matching where “underlying compatibility” matters. …read more
Source: FULL ARTICLE at Forbes Latest
Cardiovascular Systems to Present Pivotal Orbit II Coronary Data at the 2013 American College of Car
By Business Wirevia The Motley Fool
Filed under: Investing
Cardiovascular Systems to Present Pivotal Orbit II Coronary Data at the 2013 American College of Cardiology Conference
ST. PAUL, Minn., & SAN FRANCISCO–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI) (NAS: CSII) , will present data from its ORBIT II study of coronary artery disease at the 2013 American College of Cardiology (ACC) conference in San Francisco, Mar. 9-11, 2013. This marks the first time CSI will share results from this landmark pivotal trial, which is the first Investigational Device Exemption (IDE) study in history to seek approval for treating severely calcified coronary lesions.
ORBIT II is evaluating the safety and effectiveness of the company’s orbital atherectomy technology in treating this problematic subset of patients. Moderate to severe arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention, according to estimates. Moderate to severe calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse coronary events. A coronary application would open up a large, underserved market opportunity for CSI, estimated to exceed $1.5 billion annually in the United States.
CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012. CSI is targeting the end of March to submit its Premarket Approval application to the Food and Drug Administration (FDA).
|
|
|||||
ACC to talk about issues of storming court
By Andy Katz The ACC is expected to discuss the safety of court-storming and whether an SEC-like penalty structure is warranted when the conference holds its spring meetings in May, at least one athletic director told ESPN.com Friday. …read more
Source: FULL ARTICLE at ESPN Headlines
FSU vs. Pitt opens tough 2013 ACC schedule
By Heather Dinich A nationally televised Labor Day matchup between defending ACC champion Florida State and league newcomer Pittsburgh will kickoff what is the largest — and arguably the most difficult — schedule in ACC history. …read more
Source: FULL ARTICLE at ESPN Headlines
Amica Mature Lifestyles Makes Notable Cross Below Critical Moving Average
In trading on Wednesday, shares of Amica Mature Lifestyles Inc./ Style de Vie Amica Inc. (Toronto: ACC) crossed below their 200 day moving average of $9.29, changing hands as low as $9.25 per share. Amica Mature Lifestyles Inc./ Style de Vie Amica Inc. shares are currently trading off about 0.6% on the day. The chart below shows the one year performance of ACC shares, versus its 200 day moving average: …read more
Source: FULL ARTICLE at Forbes Markets
Source: ACC eyes men's hoops tourney in N.Y.
By Brett McMurphy Because of the Atlantic Coast Conference‘s increased Northeastern footprint, the ACC is interested in holding a future men’s basketball tournament in New York, an ACC school official told ESPN.
Source: FULL ARTICLE at ESPN Headlines
Daily Dividends Report: HCBK, COL, NYCB, ENR, ACC
By MarketNewsVideo Hudson City Bancorp Incorporated (HCBK) maintained its quarterly dividend of 8 cents per share. Investors of record on Monday, February 11th will be paid the dividend on Thursday, February 28th. This represents a $0.32 annualized dividend and a dividend yield of 3.73%.
Source: FULL ARTICLE at Forbes Markets
Trials Of Niacin And Atrial Fibrillation Device Will Headline American College Of Cardiology Program
By Larry Husten, Contributor Two big trials will highlight this year’s American College of Cardiology meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific‘s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation. Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The final list of trials has been posted on the ACC website.
Source: FULL ARTICLE at Forbes Latest